secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2022-01-10T23:59:59+00:00
Accession:  0001193125-22-005069
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AlloVir reports $248.1M cash at year-end 2021; JPM presentation ongoing
-----------------------------------------------------------------------

- Unaudited cash, equivalents and marketable securities total $248.1M as of Dec 31, 2021.
- Corporate presentation furnished for J.P. Morgan Healthcare Conference on Jan 10, 2022.
- AlloVir is a leader in allogeneic, off-the-shelf virus-specific T cell therapies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312522005069/0001193125-22-005069-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312522005069/d279555d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-005069

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer